Cargando…
Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
Systemic therapy for advanced hepatocellular carcinoma (HCC) has been focusing on overcoming tumor angiogenesis and immunosuppression. Myeloid-derived suppressor cells (MDSCs) promote both angiogenesis and immunosuppression in the tumor microenvironment (TME). Multiple clinical studies have demonstr...
Autores principales: | Lu, Li-Chun, Chang, Chun-Jung, Hsu, Chih-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511249/ https://www.ncbi.nlm.nih.gov/pubmed/31123667 http://dx.doi.org/10.2147/JHC.S159693 |
Ejemplares similares
-
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014) -
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
por: Zhao, Yang, et al.
Publicado: (2023) -
Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease
por: Hsieh, Ching-Chuan, et al.
Publicado: (2022) -
Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives
por: Koinis, Filippos, et al.
Publicado: (2021) -
Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma
por: Lee, Wei-Chen, et al.
Publicado: (2019)